摘要
目的比较血清抗存活素抗体水平在肺部良、恶性肿瘤之间表达的差异,为将抗存活素抗体作为非小细胞肺癌筛查指标提供依据。方法采用ELISA法检测健康体检者60名(对照组)、肺良性病变60例(肺良性病变组)、非小细胞肺癌60例(非小细胞肺癌组)血清中抗存活素抗体的含量。结果抗存活素抗体在对照组[11.7%(7/60)]中几乎不表达,在肺良性病变组中表达率为[20.0%(12/60)],两者之间表达差异无统计学意义。在非小细胞肺癌组的外周血中阳性表达率68.3%(41/60),与肺良性病变组之间表达差异有统计学意义(X^2=38.352,P〈0.01),与对照组比较差异亦有统计学意义(X^2=41.798,P〈0.01)。结论抗存活素抗体在健康人群及肺良性病变患者中不表达,而在非小细胞肺癌中高表达,可为非小细胞肺癌诊断提供重要依据,并可作为非小细胞肺癌的筛查指标。
Objective To compare the serum anti-survivin antibody levels between benign and malignant lung tumor,thus to provide evidence for using anti-survivin antibody as an indicator in non-small cell lung cancer. Methods ELISA was used to measure the level of anti-survivin antibody in healthy population ( control group, n = 60) , benign lung tumor patients ( benign lung tumor group, n = 60 ) and non-small cell lung cancer patients (non-small cell lung cancer group, n = 60). Results The anti-surviving antibody did not express 11.7% (7/60) in the control group and almost no expression 20. 0% (12/60) in the benign lung tumor group, with no significant difference between the two groups ( P 〉 0.05 ). In the non-small cell lung cancer group, the anti-survivin antibody expressed in 41 patients, which was significantly higher than those in the benign lung tumor group (X^2 = 38. 352, P 〈 0. 01 ). Conclusion Anti-survivin antibody does not express in the healthy population and the benign lung tumor patients, whereas shows high expression in non-small cell lung cancer. This finding indicates that anti-survivin antibody can provide important evidence for non-small cell lung cancer diagnosis, and can be used as an indicator for non-small lung cancer screening.
出处
《中国综合临床》
2011年第5期509-511,共3页
Clinical Medicine of China
关键词
抗存活素抗体
非小细胞肺癌
存活素
鳞癌
腺癌
肺良性病变
Anti-survivin antibody
non-small lung cancer
Survivin
Adenocarcinoma
Lung benign pathological change Squamous carcinoma